{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:01:48Z","timestamp":1770822108812,"version":"3.50.1"},"reference-count":39,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,8,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To explore the safety and therapeutic activity of combination anti\u2013B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Twenty-three patients with recurrent B-cell lymphoma received anti-CD22 epratuzumab 360 mg\/m<jats:sup>2<\/jats:sup>and anti-CD20 rituximab 375 mg\/m<jats:sup>2<\/jats:sup>monoclonal antibodies weekly for four doses each. Sixteen patients had indolent histologies (15 with follicular lymphoma) and seven had aggressive NHL (all diffuse large B-cell lymphoma [DLBCL]). Indolent patients had received a median of one (range, one to six) prior treatment, with 31% refractory to their last therapy and 81% with high-risk Follicular Lymphoma International Prognostic Index scores. Patients with DLBCL had a median of three (range, one to eight) prior regimens (14% resistant to last treatment) and 71% had high intermediate\u2013risk or high-risk International Prognostic Index scores. All patients were rituximab na\u00efve.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment was well tolerated, with toxicities principally infusion-related and predominantly grade 1 or 2. Ten (67%) patients with follicular NHL achieved an objective response (OR), including nine of 15 (60%) with complete responses (CRs and unconfirmed CRs). Four of six assessable patients (67%) with DLBCL achieved an OR, including three (50%) CRs. Median time to progression for all indolent NHL patients was 17.8 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The full-dose combination of epratuzumab with rituximab was well tolerated and had significant clinical activity in NHL, suggesting that this combination should be tested in comparison with single-agent treatment.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.13.821","type":"journal-article","created":{"date-parts":[[2005,6,15]],"date-time":"2005-06-15T03:44:08Z","timestamp":1118807048000},"page":"5044-5051","source":"Crossref","is-referenced-by-count":143,"title":["Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma"],"prefix":"10.1200","volume":"23","author":[{"given":"John P.","family":"Leonard","sequence":"first","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Ketas","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Ashe","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Fiore","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsiporah","family":"Shore","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Chadburn","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Horne","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Kovacs","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cliff L.","family":"Ding","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Wegener","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan D.","family":"Horak","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"From the Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, and Department of Pathology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY; Immunomedics Inc, Morris Plains, NJ; and Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041869"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200109000-00002"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1266"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281404"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403096"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Dorken B, Moldenhauer G, Pezzutto A, et al: HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 136:4470,1986-4479,","DOI":"10.4049\/jimmunol.136.12.4470"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.082"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0294"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835,1990-3849,","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R18","unstructured":"Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927,1998-1932,"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Hainsworth JD: Prolonging remission with rituximab maintenance therapy. Semin Oncol 31:17,2004-21,","DOI":"10.1053\/j.seminoncol.2003.12.005"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0525"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1087-3"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200201243460411"},{"key":"R23","unstructured":"Czuczman MS: CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 26:88,1999-96,"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.30766"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.4711"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0039"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0493"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001625700"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Engel P, Nojima Y, Rothstein D, et al: The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. J Immunol 150:4719,1993-4732,","DOI":"10.4049\/jimmunol.150.11.4719"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Engel P. CD22. J Biol Regul Homeost Agents 14:295,2000-298,","DOI":"10.1016\/S0924-8579(00)00140-0"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1007\/BF01518451"},{"key":"R32","unstructured":"Sharkey RM, Brenner A, Burton J, et al: Radioimmunotherapy of non-Hodgkin's lymphoma with Y-DOTA humanized anti-CD22 IgG (Y-Epratuzumab): Do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 44:2000,2003-2018,9090"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50057"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(03)00240-9"},{"key":"R35","unstructured":"Carnahan J, Wang P, Kendall R, et al: Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties. Clin Cancer Res 9:3982S,2003-3990S,"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(02)70201-7"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910560413"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-004-0019-1"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.043"},{"key":"R44","unstructured":"Leonard JP, Coleman M, Hainsworth JD, et al: Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma (MCL). Proc Am Soc Clin Oncol 22:566,2003, (abstr 2276)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.13.821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T11:22:41Z","timestamp":1683112961000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.13.821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":39,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2005,8,1]]}},"alternative-id":["10.1200\/JCO.2005.13.821"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.13.821","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,1]]}}}